Pyrazinamide susceptibility testing in mycobacterium tuberculosis: A systematic review with meta-analyses

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4499-4505

  Chang, Kwok Chiu ^a   Yew, Wing Wai ^b   Zhang, Ying ^c  

^a DEPARTMENT OF HEALTH   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; PNCA PROTEIN; PYRAZINAMIDE; UNCLASSIFIED DRUG;

ACTINOBACTERIA; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; DNA SEQUENCE; EMBASE; ENZYME ASSAY; MEDLINE; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SINGLE STRAND CONFORMATION POLYMORPHISM; SYSTEMATIC REVIEW; TUBERCULOSIS; WAYNE METHOD;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; PYRAZINAMIDE; SEQUENCE ANALYSIS, DNA;

EID: 80052860158     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00630-11     Document Type: Short Survey

References (79)

1. Ando, H., et al. 2010. Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clin. Microbiol. Infect. 16:1164-1168.
2. Aono, A., K. Hirano, S. Hamasaki, and C. Abe. 2002. Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test. Diagn. Microbiol. Infect. Dis. 44:347-352.
3. Barco, P., et al. 2006. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J. Antimicrob. Chemother. 58:930-935.
4. Bishop, K. S., et al. 2001. Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. Int. J. Tuberc. Lung Dis. 5:952-957.
5. Bönicke, R. 1962. Report on identification of mycobacteria by biochemical methods. Bull. Int. Union Tuberc. 32:13-68.
6. Brown, T. J., O. Tansel, and G. L. French. 2000. Simultaneous identification and typing of multi-drug-resistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB. J. Med. Microbiol. 49:651-656.
7. Campbell, P. J., et al. 2011. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:2032-2041.
8. Chan, R. C. Y., et al. 2007. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J. Antimicrob. Chemother. 59:866-873.
9. Chedore, P., L. Bertucci, J. Wolfe, M. Sharma, and F. Jamieson. 2010. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 48:300-301.
10. Cheng, S.-J., L. Thibert, T. Sanchez, L. Heifets, and Y. Zhang. 2000. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother. 44:528-532. (Pubitemid 30117936)
11. CLSI. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes, 2nd edition. Approved standard. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Cutler, R. R., P. Wilson, J. Villarroel, and F. V. Clarke. 1997. Evaluating current methods for determination of the susceptibility of mycobacteria to pyrazinamide, conventional, radiometric Bactec and two methods of pyrazinamidase testing. Lett. Appl. Microbiol. 24:127-132.
13. Davies, A. P., O. J. Billington, T. D. McHugh, D. A. Mitchison, and S. H. Gillespie. 2000. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J. Clin. Microbiol. 38:3686-3688.
14. Deeks, J. J., P. Macaskill, and L. Irwig. 2005. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J. Clin. Epidemiol. 58:882-893.
15. Dickinson, J. M., and D. A. Mitchison. 1970. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle 51:389-396.
16. Dormandy, J., et al. 2007. Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest 131:497-501. (Pubitemid 46280411)
17. Endoh, T., et al. 2002. Pyrazinamide resistance associated with pncA gene mutation in Mycobacterium tuberculosis in Japan. Epidemiol. Infect. 128:337-342.
18. Hannan, M. M., E. P. Desmond, G. P. Morlock, G. H. Mazurek, and J. T. Crawford. 2001. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J. Clin. Microbiol. 39:647-650.
19. Heifets, L. 1991. Drug susceptibility tests in the management of chemotherapy of tuberculosis, p. 89-122. In L. Heifets (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Boca Raton, FL.
20. Heifets, L. 1999. Antimycobacterial agents: pyrazinamide, p. 668-676. In V. L. Yu, T. C. Merigan, and S. L. Barriere (ed.), Antimicrobial therapy and vaccines. Williams & Wilkins, Baltimore, MD.
21. Heifets, L. 2002. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:11-12.
22. Hirano, K., M. Takahashi, Y. Kazumi, Y. Fukasawa, and C. Abe. 1997. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber. Lung Dis. 78:117-122.
23. Hou, L., et al. 2000. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol. Infect. 124:227-232.
24. Huang, T.-S., et al. 2003. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob. Agents Chemother. 47:3672-3673.
25. Irwig, L., P. Macaskill, P. Glasziou, and M. Fahey. 1995. Meta-analytic methods for diagnostic test accuracy. J. Clin. Epidemiol. 48:119-132.
26. Jonmalung, J., T. Prammananan, M. Leechawengwongs, and A. Chaiprasert. 2010. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol. 10:223.
27. Jureen, P., J. Werngren, J.-C. Toro, and S. Hoffner. 2008. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:1852-1854.
28. Kent, P. T., and G. P. Kubica. 1985. Public health mycobacteriology: a guide for the level III laboratory. U.S. Department of Health and Human Services, Centers for Disease Control, Atlanta, GA.
29. Krishnamurthy, A., D. Almeida, C. Rodrigues, and A. Mehta. 2004. Comparison of pyrazinamide drug susceptibility of M. tuberculosis by radiometric BACTEC and enzymatic pyrazinamidase assay. Indian J. Med. Microbiol. 22:166-168.
30. Lee, A. S. G., L. L. H. Tang, I. H. K. Lim, and S. Y. Wong. 2002. Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int. J. Infect. Dis. 6:48-51.
31. Lemaitre, N., W. Sougakoff, C. Truffot-Pernot, and V. Jarlier. 1999. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob. Agents Chemother. 43:1761-1763.
32. Lijmer, J. G., P. M. M. Bossuyt, and S. H. Heisterkamp. 2002. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat. Med. 21:1525-1537.
33. Liu, Y. P., M. A. Behr, P. M. Small, and N. Kurn. 2000. Genotypic determination of Mycobacterium tuberculosis antibiotic resistance using a novel mutation detection method, the branch migration inhibition M. tuberculosis antibiotic resistance test. J. Clin. Microbiol. 38:3656-3662.
34. Louw, G. E., et al. 2006. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis. 10:802-807.
35. Martin, A., et al. 2006. A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J. Antimicrob. Chemother. 58:327-331.
36. Marttila, H. J., et al. 1999. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob. Agents Chemother. 43:1764-1766.
37. McCammon, M. T., et al. 2005. Detection by denaturing gradient gel electrophoresis of pncA mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis isolates from the United States-Mexico border region. Antimicrob. Agents Chemother. 49:2210-2217.
38. McClatchy, J. K., A. Y. Tsang, and M. S. Cernich. 1981. Use of pyrazinamidase activity in Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob. Agents Chemother. 20:556-557.
39. McCune, R. M. J., W. McDermott, and R. Tompsett. 1956. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104:763-802.
40. McCune, R. M. J., and R. Tompsett. 1956. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J. Exp. Med. 104:737-762.
41. McDermott, W., and R. Tompsett. 1954. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 70:748-754.
42. Mestdagh, M., et al. 1999. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43:2317-2319.
43. Migliori, G. B., et al. 2007. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur. Respir. J. 30:623-626.
44. Migliori, G. B., R. Loddenkemper, F. Blasi, and M. C. Raviglione. 2007. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur. Respir. J. 29:423-427.
45. Miller, M. A., L. Thibert, F. Desjardins, S. H. Siddiqi, and A. Dascal. 1995. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J. Clin. Microbiol. 33:2468-2470.
46. Mohamed, A. M., D. R. Bastola, G. P. Morlock, R. C. Cooksey, and S. H. Hinrichs. 2004. Temperature-mediated heteroduplex analysis for detection of pncA mutations associated with pyrazinamide resistance and differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by denaturing high-performance liquid chromatography. J. Clin. Microbiol. 42:1016-1023.
47. Morlock, G. P., et al. 2000. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:2291-2295.
48. Moses, L. E., D. Shapiro, and B. Littenberg. 1993. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat. Med. 12:1293-1316.
49. Mphahlele, M., et al. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 46:3459-3464.
50. Pandey, S., S. Newton, A. Upton, S. Roberts, and D. Drinkovic. 2009. Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. Pathology 41:582-584.
51. Park, S. K., et al. 2001. pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. BMC Infect. Dis. 1:4.
52. Portugal, I., L. Barreiro, J. Moniz-Pereira, and L. Brum. 2004. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob. Agents Chemother. 48:2736-2738.
53. Reitsma, J. B., et al. 2005. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J. Clin. Epidemiol. 58:982-990.
54. Russell, J. A. 1944. The colorimetric estimation of small amounts of ammonia by the phenol-hypochlorite reaction. J. Biol. Chem. 156:457-461.
55. Salfinger, M., L. B. Reller, B. Demchuk, and Z. T. Johnson. 1989. Rapid radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. Res. Microbiol. 140:301-309.
56. Salfinger, M., and F. M. Kafader. 1987. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 265:404-407.
57. Scorpio, A., et al. 1997. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:540-543.
58. Scorpio, A., and Y. Zhang. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667.
59. Sekiguchi, J., et al. 2007. Detection of multidrug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 45:179-192.
60. Sekiguchi, J., et al. 2007. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains. J. Clin. Microbiol. 45:2802-2807.
61. Sharma, B., N. Pal, B. Malhotra, L. Vyas, and S. Rishi. 2010. Comparison of MGIT 960 & pyrazinamidase activity assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. Indian J. Med. Res. 132:72-76.
62. Sheen, P., et al. 2009. Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. J. Clin. Microbiol. 47:2937-2943.
63. Shenai, S., C. Rodrigues, M. Sadani, N. Sukhadia, and A. Mehta. 2009. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing. Indian J. Tuberc. 56:82-90.
64. Singh, P., et al. 2007. Comparative evaluation of Lowenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 45:76-80.
65. Somoskovi, A., et al. 2007. Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: identification of a species-specific pncA mutation in "Mycobacterium canettii" and the reliable and rapid predictor of pyrazinamide resistance. J. Clin. Microbiol. 45:595-599.
66. Sreevatsan, S., X. Pan, Y. Zhang, B. N. Kreiswirth, and J. M. Musser. 1997. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob. Agents Chemother. 41:636-640.
67. Stottmeier, K. D., R. E. Beam, and G. P. Kubica. 1967. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar. Am. Rev. Respir. Dis. 96:1072-1075.
68. Suzuki, Y., A. Suzuki, A. Tamaru, C. Katsukawa, and H. Oda. 2002. Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system. J. Clin. Microbiol. 40:501-507.
69. Tracevska, T., et al. 2004. Spectrum of pncA mutations in multidrug-resistant Mycobacterium tuberculosis isolates obtained in Latvia. Antimicrob. Agents Chemother. 48:3209-3210.
70. Trivedi, S. S., and S. G. Desai. 1987. Pyrazinamidase activity of Mycobacterium tuberculosis - a test of sensitivity to pyrazinamide. Tubercle 68:221-224.
71. Wade, M. M., D. Volokhov, M. Peredelchuk, V. Chizhikov, and Y. Zhang. 2004. Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn. Microbiol. Infect. Dis. 49:89-97.
72. Walter, S. D. 2002. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat. Med. 21:1237-1256.
73. WHO. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. World Health Organization, Geneva, Switzerland.
74. Yew, W. W., C. Lange, and C. C. Leung. 2011. Treatment of tuberculosis: update 2010. Eur. Respir. J. 37:441-462.
75. Yuksel, P., and O. Tansel. 2009. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey. New Microbiol. 32:153-158.
76. Zamora, J., V. Abraira, A. Muriel, K. Khan, and A. Coomarasamy. 2006. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med. Res. Methodol. 6:31.
77. Zhang, Y., S. Permar, and Z. Sun. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42-49.
78. Zhang, Y., and A. Telenti. 2000. Genetics of drug resistance in Mycobacterium tuberculosis, p. 235-254. In G. F. Hatfull and W. R. Jacobs, Jr. (ed.), molecular genetics of mycobacteria. ASM Press, Washington, DC.
79. Zhang, Y., and D. Mitchison. 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7:6-21.